Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.58 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL7474095 | 1.00 | DRD4 (0.58) | DRD4CCR3GAAALDH1A1MEN1 | |
| SCHEMBL7427238 | 0.91 | DRD4 (0.69) | DRD4CCR3GAAALDH1A1KDM4E | |
| Fumaric Acid SCHEMBL9253101 | 0.76 | CCR3 (0.60) | CCR3GAAALDH1A1MEN1KMT2A | |
| Fumaric Acid SCHEMBL9253095 | 0.76 | CCR3 (0.60) | CCR3GAAALDH1A1MEN1KMT2A | |
| Fumaric Acid SCHEMBL8569153 | 0.74 | CCR3 (0.55) | CCR3GAAALDH1A1MEN1KMT2A | |
| Maleic Acid SCHEMBL8569150 | 0.74 | CCR3 (0.55) | CCR3GAAALDH1A1MEN1KMT2A | |
| SCHEMBL2004615 | 0.74 | CCR3 (1.00) | CCR3GAAALDH1A1MEN1KMT2A | |
| SCHEMBL7977320 | 0.72 | CCR3 (0.96) | CCR3GAAALDH1A1MEN1KMT2A | |
| SCHEMBL8191786 | 0.72 | CCR3 (0.96) | CCR3GAAALDH1A1MEN1KMT2A | |
| SCHEMBL6153469 | 0.71 | GAA (0.80) | CCR3GAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996016057-A1 | CERTAIN 1-SUBSTITUTED AMINOMETHYL IMIDAZOLE AND PYRROLE DERIVATIVES; NOVEL DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| US-6002005-A | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1996016057-A1 | CERTAIN 1-SUBSTITUTED AMINOMETHYL IMIDAZOLE AND PYRROLE DERIVATIVES; NOVEL DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| US-5478934-A | Treating central nervous system disorders | NEUROGEN CORPORATION | 1995-12-26 | — | — | US | disclosed |